Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.
|Slideshows|September 16, 2019
Clinical Quiz: Rheumatoid Arthritis Flares
Patients with rheumatoid arthritis often experience flares when symptoms and functionality worsen. Predicting flares and preventing them is a key area of research in rheumatoid arthrits (RA). In this quiz, test how familiar you are with recent findings in this area.
Advertisement
Patients with rheumatoid arthritis often experience flares when symptoms and functionality worsen. Predicting flares and preventing them is a key area of research in rheumatoid arthrits (RA). In this quiz, test how familiar you are with recent findings in this area.
Advertisement
Related to this article
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement